Meeting
2022 ASCO Annual Meeting
Randomized phase 2 study evaluating efficacy and safety of inupadenant in combination with chemotherapy in adults with metastatic non–small cell lung cancer (mNSCLC) who progressed on immunotherapy.
Presenter
Mary E.R. O'Brien, MD
The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
EudraCT 2021-005487-22
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9158)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9158
Abstract #
TPS9158
Poster Bd #
133b
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.
Speaker: Wei Li, MD
Videos & Slides
2023 ASCO Annual Meeting
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
Speaker: Gregory J. Riely, MD, PhD, FASCO
Videos & Slides
2017 ASCO Annual Meeting
Implementation of Modern Eligibility in Trials: Industry Perspective
Speaker: Eric H. Rubin, MD
Videos & Slides
2024 ASCO Annual Meeting
SOGUG-NEOWIN: A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations.
Speaker: Syed A. Hussain, MD